Unobserved “Home” Induction Onto Buprenorphine
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Unobserved, or "home" buprenorphine induction is common in some clinical practices. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This review summarizes the literature on the feasibility and acceptability, safety, effectiveness, and prevalence of unobserved induction. METHODS: We searched the English language literature for studies describing unobserved buprenorphine induction and associated outcomes. Clinical studies were assessed by strength of design, bias, and internal and external validity. Surveys of provider practices and unobserved induction adoption were reviewed for prevalence data and key findings. We also examined previous review papers and international buprenorphine treatment guidelines. RESULTS: N = 10 clinical studies describing unobserved induction were identified: 1 randomized controlled trial, 3 prospective cohort studies, and 6 retrospective cohort studies. The evidence supports the feasibility of unobserved induction, particularly in office-based primary care practices. Evidence is weak to moderate in support of no differences in adverse event rates between unobserved and observed inductions. There is insufficient or weak evidence in terms of any or no differences in overall effectiveness (treatment retention, medication adherence, illicit opioid abstinence, other drug use). N = 9 provider surveys assessed unobserved induction: observed induction logistics are seen as barriers to buprenorphine prescribing; unobserved induction appears widespread in specific locations. International guidelines reviewed emphasize clinician or pharmacist observed induction (the United States, the United Kingdom, France, Australia); only one (Denmark) explicitly endorses unobserved induction. CONCLUSIONS: There is insufficient evidence supporting unobserved induction as more, less, or as effective as observed induction. However, the predominantly observational and naturalistic studies of unobserved induction reviewed, all of which have significant sources of bias and limited external validity, document feasibility and low rates of adverse events. Unobserved induction seems to be widely adopted in US and French regional provider surveys. Prescribers, policy makers, and patients should balance the benefits of observed induction such as maximum clinical supervision with the ease-of-use and comparable safety profile of unobserved induction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540 · cited 1×
“…buprenorphine treatment trials using observed induction methods, acute precipitated withdrawal was not a common adverse event, compared to headache, nausea, and insomnia, and is typically not listed as occurring with any regularity (Ling et al., 1996, 1998; Fudala et al., 2003, Weiss et al., 2011).”
BackgroundBuprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
A Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence
Ling, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050035005 · Cited by 366 · cited 1×
“…buprenorphine treatment trials using observed induction methods, acute precipitated withdrawal was not a common adverse event, compared to headache, nausea, and insomnia, and is typically not listed as occurring with any regularity (Ling et al., 1996, 1998; Fudala et al., 2003, Weiss et al., 2011).”
BackgroundCounseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351 · cited 1×
“…current US national prescribing guidelines published by the Center for Substance Abuse Treatment (CSAT) of the Substance Abuse and Mental Health Service Administration (SAMHSA) addressing buprenorphine induction describe observed induction as standard practice (CSAT, 2004; Fiellin et al., 2004).”
BackgroundSelf-citationTreating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings
Mintzer, I. L., Eisenberg, M., Terra, M., MacVane, C., Himmelstein, D. U., & Woolhandler, S. (2007) · The Annals of Family Medicine · doi:10.1370/afm.665 · Cited by 117 · cited 4×
“In the observational studies comparing unobserved versus observed induction, ranges for successful unobserved induction were 60% to 93% (Alford et al., 2007; Mintzer et al., 2007; Gunderson et al., 2010; Cunningham et al., 2011; Lee et al., 2012).”
BackgroundInfluential
Research works printed but not linked: 27
- Albright, 2010, Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment., J Addict Med, 4, 197, 10.1097/ADM.0b013e3181c816f3 · DOI
- Alford, 2007, Treating homeless opioid dependent patients with buprenorphine in an office-based setting., J Gen Intern Med, 22, 171, 10.1007/s11606-006-0023-1 · DOI · Paper page
- Cunningham, 2011, A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions., J Subst Abuse Treat, 40, 349, 10.1016/j.jsat.2010.12.002 · DOI · Paper page
- Cunningham, 2007, Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians., J Gen Intern Med, 22, 1325, 10.1007/s11606-007-0264-7 · DOI
- Doolittle, 2011, A case series of buprenorphinenaloxone treatment in a primary care practice., Subst Abus, 32, 262, 10.1080/08897077.2011.599256 · DOI
- Egan, 2010, The physician clinical support system-buprenorphine (PCSS-B): a novel project to expandimprove buprenorphine treatment., J Gen Intern Med, 25, 936, 10.1007/s11606-010-1377-y · DOI · Paper page
- Fiellin, 2004, Consensus statement on office-based treatment of opioid dependence using buprenorphine., J Subst Abuse Treat, 27, 153, 10.1016/j.jsat.2004.06.005 · DOI
- Gibson, 2003, A comparison of buprenorphrine treatment in clinic and primary care settings: a randomised trial., Med J Aust, 179, 38, 10.5694/j.1326-5377.2003.tb05417.x · DOI · Paper page
- Gunderson, 2011, Buprenorphine induction: a major barrier for physician adoption of office-based opioid dependence treatment., J Addict Med, 5, 304, 10.1097/ADM.0b013e31821ee8fe · DOI
- Gunderson, 2006, Evaluation of a combined online and in person training in the use of buprenorphine., Subst Abus, 27, 39, 10.1300/J465v27n03_06 · DOI
- Gunderson, 2010, Unobserved versus observed office buprenorphinenaloxone induction: a pilot randomized clinical trial., Addict Behav, 35, 537, 10.1016/j.addbeh.2010.01.001 · DOI
- Kissin, 2006, Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence., J Addict Dis, 25, 91, 10.1300/J069v25n04_09 · DOI · Paper page
- Lee, 2009, Home buprenorphinenaloxone induction in primary care., J Gen Intern Med, 24, 226, 10.1007/s11606-008-0866-8 · DOI
- Lee, 2012, Buprenorphine-naloxone maintenance following release from jail., Subst Abus, 33, 40, 10.1080/08897077.2011.620475 · DOI
- Lintzeris, 2002, A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal., Addiction, 97, 1395, 10.1046/j.1360-0443.2002.00215.x · DOI · Paper page
- Lucas, 2010, Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial., Ann Intern Med, 152, 704, 10.7326/0003-4819-152-11-201006010-00003 · DOI
- Moher, 2009, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement., J Clin Epidemiol, 62, 1006, 10.1016/j.jclinepi.2009.06.005 · DOI · Paper page
- Moore, 2007, Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients., J Gen Intern Med, 22, 527, 10.1007/s11606-007-0129-0 · DOI · Paper page
- Netherland, 2009, Factors affecting willingness to provide buprenorphine treatment., J Subst Abuse Treat, 36, 244, 10.1016/j.jsat.2008.06.006 · DOI · Paper page
- Soeffing, 2009, Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year., J Subst Abuse Treat, 37, 426, 10.1016/j.jsat.2009.05.003 · DOI
- Sohler, 2010, Home- versus office-based buprenorphine inductions for opioid-dependent patients., J Subst Abuse Treat, 38, 153, 10.1016/j.jsat.2009.08.001 · DOI · Paper page
- Stein, 2005, Buprenorphine retention in primary care., J Gen Intern Med, 20, 1038, 10.1111/j.1525-1497.2005.0228.x · DOI · Paper page
- Thomas, 2008, Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists., Psychiatr Serv, 59, 909, 10.1176/ps.2008.59.8.909 · DOI
- Turner, 2005, Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence., Arch Intern Med, 165, 1769, 10.1001/archinte.165.15.1769 · DOI
- Vignau, 2001, Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients J Subst Abuse T, reat, 21, 135
- Walley, 2008, Office-based management of opioid dependence with buprenorphine: clinical practices and barriers., J Gen Intern Med, 23, 1393, 10.1007/s11606-008-0686-x · DOI · Paper page
- Whitley, 2010, Factors associated with complicated buprenorphine inductions., J Subst Abuse Treat, 39, 51, 10.1016/j.jsat.2010.04.001 · DOI
Cited by
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Management of opioid use disorders: a national clinical practice guideline
Bruneau, J., Ahamad, K., Goyer, M.-È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., & Wood, E. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170958 · Cited by 412
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1652 · Cited by 130
Sokol, R., Albanese, M., Chew, A., Early, J., Grossman, E., Roll, D., Sawin, G., Wu, D. J., & Schuman-Olivier, Z. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0176-y · Cited by 14
Implementing Group Visits for Opioid Use Disorder: A Case Series
Sokol, R., Albanese, M., Albanese, C., Coste, G., Grossman, E., Morrill, D., Roll, D., Sobieszczyk, A., & Schuman-Olivier, Z. (2020) · Substance Abuse · doi:10.1080/08897077.2019.1635958 · Cited by 12
“After starting B/N, patients receive follow-up telephone call 3–5 days later.(12,20,21) When prescriptions are provided: At the end of group Individual visits offered: Yes, 3–4 patients are seen individually for 15-minute appointments after the group (identified ahead of time by the B/Nprovider and as needed) Monitori…”
BackgroundMethod
Metadata
- Authors
- Lee, J. D., Vocci, F., & Fiellin, D. A.
- Venue
- Journal of Addiction Medicine
- Published
- 2014-09
- Volume
- 8
- Issue
- 5
- Pages
- 299-308
- ISSN
- 1932-0620 (ISSN-L)
- OpenAlex
- W2064271499
- Cited by
- 58
- References
- 6
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unobserved “Home” Induction Onto Buprenorphine. https://app.cochat.ai/papers/10.1097/adm.0000000000000059
- The paper
- Lee, J. D., Vocci, F., & Fiellin, D. A. (2014). Unobserved “Home” Induction Onto Buprenorphine. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.